Diversify Wealth Management LLC Has $3.51 Million Holdings in Edwards Lifesciences Corporation (NYSE:EW)

Diversify Wealth Management LLC raised its stake in Edwards Lifesciences Corporation (NYSE:EW - Free Report) by 22.8% in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 45,982 shares of the medical research company's stock after acquiring an additional 8,541 shares during the quarter. Diversify Wealth Management LLC's holdings in Edwards Lifesciences were worth $3,508,000 at the end of the most recent quarter.

A number of other institutional investors also recently made changes to their positions in EW. Crowley Wealth Management Inc. acquired a new position in Edwards Lifesciences in the fourth quarter valued at $26,000. Vega Investment Solutions acquired a new stake in Edwards Lifesciences during the fourth quarter worth about $27,000. Millstone Evans Group LLC acquired a new stake in Edwards Lifesciences during the fourth quarter worth about $29,000. Global X Japan Co. Ltd. increased its stake in Edwards Lifesciences by 116.1% during the first quarter. Global X Japan Co. Ltd. now owns 402 shares of the medical research company's stock worth $29,000 after acquiring an additional 216 shares during the last quarter. Finally, Tradewinds Capital Management LLC increased its stake in Edwards Lifesciences by 102.5% during the first quarter. Tradewinds Capital Management LLC now owns 405 shares of the medical research company's stock worth $29,000 after acquiring an additional 205 shares during the last quarter. 79.46% of the stock is owned by institutional investors and hedge funds.

Edwards Lifesciences Stock Down 0.9%

NYSE EW traded down $0.73 during trading on Friday, hitting $78.07. 3,780,176 shares of the company traded hands, compared to its average volume of 5,256,833. The company has a current ratio of 4.45, a quick ratio of 3.66 and a debt-to-equity ratio of 0.06. The business has a fifty day simple moving average of $76.25 and a 200 day simple moving average of $73.36. The company has a market capitalization of $45.79 billion, a P/E ratio of 11.15, a PEG ratio of 3.96 and a beta of 1.11. Edwards Lifesciences Corporation has a 12 month low of $58.93 and a 12 month high of $92.88.

Edwards Lifesciences (NYSE:EW - Get Free Report) last released its earnings results on Wednesday, April 23rd. The medical research company reported $0.64 earnings per share for the quarter, topping analysts' consensus estimates of $0.60 by $0.04. The business had revenue of $1.41 billion for the quarter, compared to the consensus estimate of $1.40 billion. Edwards Lifesciences had a return on equity of 16.62% and a net margin of 75.48%. The firm's revenue for the quarter was up 6.2% compared to the same quarter last year. During the same period last year, the business earned $0.66 earnings per share. As a group, sell-side analysts predict that Edwards Lifesciences Corporation will post 2.45 EPS for the current year.

Insider Transactions at Edwards Lifesciences

In other Edwards Lifesciences news, VP Daveen Chopra sold 1,500 shares of the company's stock in a transaction on Thursday, May 22nd. The shares were sold at an average price of $75.08, for a total transaction of $112,620.00. Following the completion of the sale, the vice president owned 33,496 shares in the company, valued at approximately $2,514,879.68. The trade was a 4.29% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO Bernard J. Zovighian sold 5,980 shares of Edwards Lifesciences stock in a transaction dated Monday, May 5th. The shares were sold at an average price of $74.91, for a total value of $447,961.80. Following the completion of the sale, the chief executive officer directly owned 58,284 shares in the company, valued at $4,366,054.44. This represents a 9.31% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 40,348 shares of company stock worth $2,977,683 over the last ninety days. 1.29% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

Several brokerages have commented on EW. Piper Sandler upped their price target on Edwards Lifesciences from $80.00 to $83.00 and gave the stock an "overweight" rating in a research note on Tuesday, May 13th. Canaccord Genuity Group increased their target price on Edwards Lifesciences from $71.00 to $75.00 and gave the company a "hold" rating in a research note on Friday, April 25th. Citigroup reiterated a "buy" rating and issued a $95.00 target price (up previously from $84.00) on shares of Edwards Lifesciences in a research note on Thursday, May 22nd. Dbs Bank upgraded Edwards Lifesciences to a "hold" rating in a research note on Monday, June 2nd. Finally, Robert W. Baird increased their target price on Edwards Lifesciences from $72.00 to $75.00 and gave the company a "neutral" rating in a research note on Thursday, April 24th. One analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and eleven have given a buy rating to the company's stock. Based on data from MarketBeat, the company presently has a consensus rating of "Hold" and a consensus price target of $80.40.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.